ArticleEMBO molecular medicine2021
The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors.
Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.The Journal of infectious diseases · 2024Trial
- Respiratory Syncytial Virus F Protein Adjuvanted with a Carbomer-Based Adjuvant Induces Protective Humoral Response in Mice.ACS omega · 2026Article
- RSV vaccine development: advances and fusion protein-focused strategies.Frontiers in immunology · 2026Review
- Immunogenicity and memory B-cell potency induced by an inactivated COVID-19 vaccine in pregnant women.Molecular medicine (Cambridge, Mass.) · 2025Article
- Highly Effective mRNA-LNP Vaccine Against Respiratory Syncytial Virus (RSV) in Multiple Models.Vaccines · 2025Article
- Favorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits.Vaccines · 2024Article
- RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy.Obstetrics & gynecology science · 2024Article
- Genomic Evolution and Surveillance of Respiratory Syncytial Virus during the 2023-2024 Season.Viruses · 2024Article
- Respiratory Syncytial Virus Infection in Older Adults: An Update.Drugs & aging · 2024Review
- Assessing the protection elicited by virus-like particles expressing the RSV pre-fusion F and tandem repeated G proteins against RSV rA2 line19F infection in mice.Respiratory research · 2024Article
- Experimental trials of predicted CD4Frontiers in immunology · 2024Article
- From setbacks to success: lessons from the journey of RSV vaccine development.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Host Responses to Respiratory Syncytial Virus Infection.Viruses · 2023Review
- A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F.Science China. Life sciences · 2023Article
- Review
- Article
- A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein.Frontiers in immunology · 2022Article
- The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors.EMBO molecular medicine · 2021Article
- Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.International journal of biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is the leading cause of death from lower respiratory tract infection in infants and children, and is responsible for considerable morbidity and mortality in older adults. Vaccines for pregnant women and elderly which are in phase III clinical studies target people with pre-existing natural immunity against RSV. To investigate the background immunity which will be impacted by vaccination, we single cell-sorted human memory B cells and dissected functional and genetic features of neutralizing antibodies (nAbs) induced by natural infection. Most nAbs recognized both the prefusion and postfusion conformations of the RSV F-protein (cross-binders) while a smaller fraction bound exclusively to the prefusion conformation. Cross-binder nAbs used a wide array of gene rearrangements, while preF-binder nAbs derived mostly from the expansion of B-cell clonotypes from the IGHV1 germline. This latter class of nAbs recognizes an epitope located between Site Ø, Site II, and Site V on the F-protein, identifying an important site of pathogen vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.